Ferriprox

(Deferiprone)

ApprovedSmall molecule

Chiesi Farmaceutici S.p.A.

Ferriprox is one of 512 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

511

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionApproved

Cognitive ImpairmentActive, not recruiting

StrokeApproved

Friedreich AtaxiaApproved

AceruloplasminemiaApproved

Acute Myocardial InfarctionActive, not recruiting

Wolfram SyndromeActive, not recruiting

Parkinson DiseaseApproved

Pantothenate Kinase-Associated NeurodegenerationActive, not recruiting

Beta-Thalassemia MajorActive, not recruiting

HIV InfectionApproved

Approved

Cognitive ImpairmentPhase 1

Active, not recruiting

StrokeApproved

Approved

Friedreich AtaxiaApproved

Approved

AceruloplasminemiaApproved

Approved

Acute Myocardial InfarctionPhase 2

Active, not recruiting

Wolfram SyndromePhase 2/Phase 3

Active, not recruiting

Parkinson DiseaseApproved

Approved

Pantothenate Kinase-Associated NeurodegenerationPhase 3

Active, not recruiting

Beta-Thalassemia MajorPhase 2

Active, not recruiting

Showing 10 of 23 indications

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Ferriprox

Chiesi Farmaceutici S.p.A.

Approved

1 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Uloric

Takeda

Preclinical

3 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Lorelco

Sanofi

Preclinical

1 8

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Sickle Cell Disease

NCT07023666

Q3 2029

Phase 2Recruiting

Acute Myocardial Infarction

NCT05604131

Clinical

Trials by Indication[1]

Iron Overload3 trials

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

Completed·AApoPharma·Phase 2·NCT03802916·30 enrolled

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

Completed·LLipomed·Phase 2·NCT00349453·24 enrolled

Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients

Completed·LLipomed·Phase 3·NCT00350662·95 enrolled

Parkinson's Disease3 trials

Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease

Completed·UUniversity Hospital, Lille·Phase 2/3·NCT00943748·40 enrolled

A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease

Completed·IImperial College London·Phase 2·NCT01539837·22 enrolled

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

Completed·UUniversity Hospital, Lille·Phase 2·NCT02655315·372 enrolled

Sickle Cell Disease3 trials

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Recruiting·IInova Health Care Services·Phase 2·NCT07023666·100 enrolled

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Terminated·AApoPharma·Phase 4·NCT02041299·230 enrolled

Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

Terminated·AApoPharma·Approved·NCT02443545·134 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients

Completed·AApoPharma·Phase 3·NCT00529152·100 enrolled

Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children

Completed·CChiesi Canada Corp·Phase 4·NCT03591575·64 enrolled

Ataxia2 trials

A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

Completed·AApoPharma·Phase 2·NCT00897221·36 enrolled

A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

Completed·AApoPharma·Phase 1/2·NCT00530127·80 enrolled

25 more indications

Intravenous2 trials

Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects

Completed·AApoPharma·Phase 1·NCT02456558·30 enrolled

A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers

Completed·AApoPharma·Phase 1·NCT01989455·64 enrolled

Pantothenate Kinase-Associated Neurodegeneration2 trials

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

Completed·AApoPharma·Phase 3·NCT02174848·68 enrolled

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

Completed·AApoPharma·Phase 3·NCT01741532·89 enrolled

Efficacy2 trials

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

Completed·AAzienda Ospedaliera V. Cervello·Phase 4·NCT00733811·213 enrolled

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Completed·CConsorzio per Valutazioni Biologiche e Farmacologiche·Phase 3·NCT01825512·435 enrolled

Amyotrophic Lateral Sclerosis2 trials

Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients

Completed·UUniversity Hospital, Lille·Phase 2·NCT02164253·23 enrolled

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis

Completed·UUniversity Hospital, Lille·Phase 2/3·NCT03293069·372 enrolled

Thalassemia2 trials

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Completed·CCarelon Research··NCT00000623·1,000 enrolled

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

Unknown status·RRoyal Brompton & Harefield NHS Foundation Trust·Phase 4·NCT00103753·65 enrolled

Single Dose1 trial

Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration

Completed·SSocraTec R&D GmbH·Phase 1·NCT02980458·25 enrolled

Wolfram syndrome1 trial

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Unknown status·HHadassah Medical Organization·Phase 2/3·NCT02882477·20 enrolled

Tics1 trial

Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects

Completed·AApoPharma·Phase 1·NCT02191657·26 enrolled

Heart Disease1 trial

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

Approved for marketing·—··NCT00293098

Neurodegeneration1 trial

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Unknown status·EEnte Ospedaliero Ospedali Galliera·Phase 2·NCT00907283·20 enrolled

Beta-Thalassemia Major1 trial

An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients

Unknown status·—·Phase 2/3·NCT02173951·64 enrolled

Chronic Kidney Disease1 trial

Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent

Withdrawn·CCorMedix·Phase 3·NCT01391520

Oral1 trial

Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

Completed·AApoPharma·Phase 1·NCT02442310·20 enrolled

MPA1 trial

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Completed·AApoPharma·Phase 1·NCT02465489·20 enrolled

Acute Myocardial Infarction1 trial

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Recruiting·RRohan Dharmakumar·Phase 2·NCT05604131·89 enrolled

Combination Therapy1 trial

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Terminated·CCarelon Research·Phase 2·NCT00115349·20 enrolled

Pilot Study1 trial

Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers

Completed·AApoPharma·Phase 1·NCT02189941·11 enrolled

Dementia1 trial

Deferiprone to Delay Dementia (The 3D Study)

Completed·NNeuroscience Trials Australia·Phase 2·NCT03234686·81 enrolled

Renal Impairment1 trial

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

Completed·AApoPharma·Phase 4·NCT01770652·32 enrolled

Cognitive impairment1 trial

A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment

Withdrawn·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT02878538

Low Risk1 trial

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Completed·SSheba Medical Center·Phase 2·NCT02477631·19 enrolled

Parkinson's1 trial

Study of Parkinson's Early Stage With Deferiprone

Completed·AApoPharma·Phase 2·NCT02728843·140 enrolled

PKAN1 trial

Compassionate Use of Deferiprone in Patients With PKAN

No longer available·CChiesi Canada Corp··NCT02635841

Oxidative Stress1 trial

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes

Completed·UUniversity Hospital, Lille·N/A·NCT02880033·90 enrolled

Unspecified1 trial

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

Completed·AApoPharma·Phase 4·NCT01860703·50 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 20, 2018

FERRIPROX

NDA NDA208030

Jul 25, 2019

FERRIPROX

NDA NDA021825

May 19, 2020

FERRIPROX

NDA NDA212269

Sources

References

[1]
ClinicalTrials.gov — 43 trial records for Deferiprone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Deferiprone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Deferiprone. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA212269). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Ferriprox. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Chiesi Farmaceutici S.p.A.

Patent Landscape[5]

Patent Cliff

Oct 26, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8703156Oct 26, 2029

11357731Oct 25, 2038

11723874Oct 25, 2038

10780055Oct 25, 2038

11458103Oct 25, 2038

2 more patents

10940116Oct 25, 2038

10940115Oct 25, 2038

Ferriprox

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2029

Trials by Indication[1]

Iron Overload3 trials

Parkinson's Disease3 trials

Sickle Cell Disease3 trials

Safety and Efficacy2 trials

Ataxia2 trials

Intravenous2 trials

Pantothenate Kinase-Associated Neurodegeneration2 trials

Efficacy2 trials

Amyotrophic Lateral Sclerosis2 trials

Thalassemia2 trials

Single Dose1 trial

Wolfram syndrome1 trial

Tics1 trial

Heart Disease1 trial

Neurodegeneration1 trial

Beta-Thalassemia Major1 trial

Chronic Kidney Disease1 trial

Oral1 trial

MPA1 trial

Acute Myocardial Infarction1 trial

Combination Therapy1 trial

Pilot Study1 trial

Dementia1 trial

Renal Impairment1 trial

Cognitive impairment1 trial

Low Risk1 trial

Parkinson's1 trial

PKAN1 trial

Oxidative Stress1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News